Journal: Cancer Research

Article Title: HPV-16 E7 Reveals a Link between DNA Replication Stress, Fanconi Anemia D2 Protein, and Alternative Lengthening of Telomere–Associated Promyelocytic Leukemia Bodies

doi: 10.1158/0008-5472.can-08-0224

Figure Lengend Snippet: Figure 3. FANCD2-positive APBs contain known APB components as well as BRCA2 and MUS81. Coimmunofluorescence microscopic analysis of U-2 OS cells stably expressing HPV-16 E7 for FANCD2 in combination with RPA32, BLM, RAD51, MRE11, BRCA2/FANCD1, or MUS81. MUS81-HA was transiently overexpressed in cells before processing for immunofluorescence staining for HA and FANCD2. Insets, APBs indicated by arrows. Nuclei stained with DAPI. Bar, 10 Am.

Article Snippet: Primary antibodies used for immunoblotting and immunofluorescence were 53BP1 (Novus Biologicals), actin (Sigma), ATM (Genetex), phosphorylated ATM at serine 1981 (Novus Biologicals), ATR (Genetex), BLM (Bethyl), BRCA2 (Calbiochem), 5¶-bromo-2¶ deoxyuridine (BrdUrd; Roche Diagnostics), FANCD2 (Genetex), HA (Santa Cruz Biotechnology), HPV-16 E7 (Santa Cruz Biotechnology), g-H2AX (Trevigen), MRE11 (Genetex), PML (Santa Cruz Biotechnology), RAD51 (Genetex), RPA32 (Lab Vision), and TRF2 (Imgenex).

Techniques: Stable Transfection, Expressing, Immunofluorescence, Staining

Journal: Frontiers in Oncology

Article Title: Prognostic value and experimental validation of atherosclerosis-derived pathogenic genes in colorectal cancer

doi: 10.3389/fonc.2025.1728087

Figure Lengend Snippet: Validation of the expression of 6 hub genes in CRC and AS by molecular biology experiments. (A-F) RT-qPCR validation of the differential expression of prognostic genes between normal and tumor tissues in CRC patients. (G) Western blot validation of the differential expression of 2 newly identified genes (HMMR and PALB2) between normal and tumor tissues in CRC. (H) Quantitative analysis of the relative grayscale values of Western blot bands for the 2 newly identified genes (HMMR and PALB2) in normal and tumor tissues of CRC. Data are presented as mean ± standard deviation (SD), with statistical significance indicated as * p < 0.05, *** p < 0.001, and **** p < 0.0001. ns indicates no statistical significance.

Article Snippet: The membrane was blocked with QuickBlockTM Blocking Buffer for Western Blot (Beyotime Biotechnology, Jiangsu, China) at room temperature for 1 h, washed with TBST, and incubated overnight at 4°C with primary antibodies: HMMR (1:2000, 15820-1-AP, Proteintech), PALB2 (1:2000, 14340-1-AP, Proteintech), and β-actin (1:10,000, 66009-1-Ig, Proteintech).

Techniques: Biomarker Discovery, Expressing, Quantitative RT-PCR, Quantitative Proteomics, Western Blot, Standard Deviation

Journal: Frontiers in Oncology

Article Title: Prognostic value and experimental validation of atherosclerosis-derived pathogenic genes in colorectal cancer

doi: 10.3389/fonc.2025.1728087

Figure Lengend Snippet: IHC staining validation. (A) The differential expression of PALB2 and HMMR in CRC tissues compared with normal tissues; (B) displays the differential expression of HMMR , PALB2 and PRR11 in AS tissues versus normal tissues. * p < 0.05.

Article Snippet: The membrane was blocked with QuickBlockTM Blocking Buffer for Western Blot (Beyotime Biotechnology, Jiangsu, China) at room temperature for 1 h, washed with TBST, and incubated overnight at 4°C with primary antibodies: HMMR (1:2000, 15820-1-AP, Proteintech), PALB2 (1:2000, 14340-1-AP, Proteintech), and β-actin (1:10,000, 66009-1-Ig, Proteintech).

Techniques: Immunohistochemistry, Biomarker Discovery, Quantitative Proteomics

Journal: Molecular cell

Article Title: Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency

doi: 10.1016/j.molcel.2021.06.011

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Antibodies for western blot analysis included anti-β-actin (Sigma), anti-FANCJ (E67), anti-BRCA1 (Cell Signaling Technology), anti-p21 (Cell Signaling Technology), anti-CHD4 (Abcam), anti-BRCA2 (Abcam), anti-53BP1 (Novus Biological), anti-RADX (CXorf57, Abcam), anti-RPA70/RPA1 (Cell Signaling Technology), anti-RPA32/RPA2 (Abcam), anti-FEN1 (Abcam), anti-PARP1 (Abcam), anti-XRCC1 (Abcam), anti-LIG1 (Santa Cruz), anti-LIG3 (GeneTex) and anti-H2B (Cell Signaling Technology), anti-Cleaved Caspase-3 (Cell Signaling Technology) and anti-PARP (Cleaved PARP1, Cell Signaling Technology).

Techniques: Recombinant, Electron Microscopy, Plasmid Preparation, Imaging, CCK-8 Assay, CRISPR, shRNA, Negative Control, Construct, Software, Transfection, DNA Extraction